Curing the World One Patient at a Time
TOLL FREE: 855.251.9116

Dx Breast Cancer and Related Symptoms Treatments: Read More...


$
Observation:
Breast Cancer

The Merck Manual Home Edition states that:
"Breast cancer is the second most common cancer among women after skin cancer and, of cancers, is the second most common cause of death among women after lung cancer. In 2006, breast cancer was diagnosed in about 213,000 women in the United States. About one fifth of them will die of it".

Medications Used in Treatment
1. Progestins: MPA® (medroxyprogesterone acetate)
2. Antifolates: Rheumatrex®/ methotrexate
3. Androgens: nandrolone, stanozolol
4. Estrogen Antagonists: Tamoxifen®
5. Aromatase Inhibitors: Femara®/ letrozole
6. Kinase Inhibitors: Imbruvica®
7. Alklating Drugs: Cytoxan®
8. RANKL Inhibitors: Prolia®
9. Misc: Abraxane®: paclitaxel nanoparticles of the active ingredient in Taxol® was recently approved by the F.D.A. for the treatment of breast cancer.
10. Microtubule Inhibitors: Taxotene
11. Anthracyclines: doxorubicin
12.HER2 Receptor Antagonists: Herceptin®, Nerlynx®
13. Gonadrotropin Releasing Hormone Agonists: Lupron®
14. Nucleoside Metabolic Inhibitors: Adrucil® / fluorouracil

Suggested Links:
*N.H.S. United Kingdom
*Medscape on Breast Cancer

*[Editor] Based on the Women's Health Initiative, the use in menopausal women of synthetic estrogens (Premarin®) and synthetic progestins (Provera®) increases the risk of breast cancer. In both the United States and the United Kingdom, restricting Provera® (Estrogen only arm in the W.H.I./US) and substituting Aygestin for Provera®/U.K., resulted on normalizing the of risk. Two F.D.A. approved anabolic steroids have been used in menopausal women with breast cancer. Stanozolol has been used in patients with advanced metastatic carcinoma with almost half having a positive response. Nandrolone has been combined with the aromatase inhibitor (tamoxifen) for prophylaxis against breast cancer recurrences. The use of these two anabolic steroids do not raise, rather they lower estradiol levels. These anabolic steroids raise the quality of life: the women have less symptoms of menopause: they offer treatments for the hot flushes, insomnia, osteoporosis, poor memory and loss of libido. The two anabolic steroids used together will produce an atrophic endometrium, so the concern of uterine bleeding with aromatase inhibitors (tamoxifen, anastrozole) is minimized.

*[Editor] A recent peer reviewed article showed in a 5-year follow up (10-year planned study) that the use of a testosterone implant in post-menopausal women was associated in a 50% drop in risk of breast cancer developing compared to placebo, the WHI and other large scale studies. The two active groups had
1) testosterone implant and 2) testosterone implant with an estrogen aromatase inhibitor.


*[Editor] Two new developments in breast cancer:
Cancer Research 2014 reported that "Recent use of oral contraceptives " was linked to a 50% increased risk of breast cancer versus never using oral contraceptives. The risk was stratified upward with use of higher dose estrogen, ethynodiol acetate and triphasis (2.7, 2.6 and 3.1 respectively times non-user risk). Other low dose estrogen contraceptives.
Topical tamoxifen may be equal in effectiveness as Oral Tamoxifen in ductal carcinoma in situ(DCIS) said Dr. O. Lee in the Journal of Clinical Cancer research.


Copyrighted 2014©